Alnylam Pharmaceuticals
ALNY
224.41
+0.47
+0.21%
Alnylam Pharmaceuticals
US · ALNY
#627 by market cap
Listed 1970
224.41
+0.47
+0.21%
Live - 5344 symbols - heartbeat 132s ago
· 2026-10-08 06:06
Pre-market
224.50
+0.04%
After-hours
224.41
0.00%
Overnight
224.32
-0.04%
- Market cap
- 30.03B
- P/E (TTM)i
- 39.10
- P/Bi
- 22.17
- EPSi
- 2.33
- Div yieldi
- 0.00%
- 52W posi
- 9%
Reader sentiment
Are you bullish or bearish on ALNY?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 3 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.4 percentage points.
Institutional ownership
- Held by institutions
- 101.66% -0.44pp
- Institutions
- 1,005 -3
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund87.65%
Hedge Fund5.72%
Public Company2.90%
Sovereign Wealth Fund1.89%
Government Pension Fund1.53%
Private Company0.80%
VC/PE Fund0.77%
Individual/Insider0.39%
Insurance Company0.21%
Top holders
Capital Research
15.71%
FMR
10.66%
BlackRock
8.15%
Vanguard Capital Management, LLC
5.15%
T. Rowe Price Group, Inc.
5.08%
Vanguard Portfolio Management, LLC
4.89%
Invesco Capital Management LLC
2.73%
State Street Global Advisors
2.66%
Geode Capital Management, LLC
1.97%
Baillie Gifford
1.82%
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 31 buys · 17 sells
| Name | Role | Stake |
|---|---|---|
| Phillip Sharp | Co-Founder, Member of the Scientific Advisory Board & Independent Director | 0.20% |
| Yvonne Greenstreet | Chief Executive Officer | 0.05% |
| Jeffrey Poulton | Chief Financial Officer | 0.03% |
| David E. Pyott | Independent Director | 0.02% |
| Amy W. Schulman | Chair of the Board & Lead Independent Director | 0.02% |
| Michael Bonney | Non-Independent Director | 0.01% |
| Tolga Tanguler | Executive Vice President | 0.01% |
| Pushkal Garg | Chief Medical Officer and Executive VP of Development & Medical Affairs | 0.01% |
| Kevin Fitzgerald | Senior VP, Head of Research & Chief Scientific Officer | 0.01% |
| Melissa McLaughlin | Chief Human Resources Officer | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-01 | Bryan Supran | Chief Legal Officer | Intent to Sell (Form 144) | -1,758 | $226.88 |
| 2026-09-18 | Yvonne Greenstreet | Chief Executive Officer | Other Acquisition | +107 | -- |
| 2026-05-31 | David E. Pyott | Independent Director | Derivative Exercise and Sale | -3,830 | $297.71–302.65 |
| 2026-05-31 | Benjamin Cravatt | Director | Other Derivative Acquisition | +4,393 | $295.63 |
| 2026-05-19 | Peter Kellogg | Independent Director | Other Acquisition | +671 | -- |
| 2026-05-19 | Peter Kellogg | Independent Director | Other Derivative Acquisition | +1,441 | $298.48 |
| 2026-05-19 | David E. Pyott | Independent Director | Other Acquisition | +671 | -- |
| 2026-05-19 | David E. Pyott | Independent Director | Other Derivative Acquisition | +1,441 | $298.48 |
| 2026-05-19 | Charles Sigal | Independent Director | Other Acquisition | +671 | -- |
| 2026-05-19 | Charles Sigal | Independent Director | Other Derivative Acquisition | +1,441 | $298.48 |
| 2026-05-19 | Margaret Hamburg | Independent Director | Other Acquisition | +671 | -- |
| 2026-05-19 | Margaret Hamburg | Independent Director | Other Derivative Acquisition | +1,441 | $298.48 |
| 2026-05-19 | Amy W. Schulman | Chair of the Board & Lead Independent Director | Other Acquisition | +838 | -- |
| 2026-05-19 | Amy W. Schulman | Chair of the Board & Lead Independent Director | Other Derivative Acquisition | +1,802 | $298.48 |
| 2026-05-19 | Dennis Ausiello | Member of the Scientific Advisory Board & Independent Director | Other Acquisition | +671 | -- |
| 2026-05-19 | Dennis Ausiello | Member of the Scientific Advisory Board & Independent Director | Other Derivative Acquisition | +1,441 | $298.48 |
| 2026-05-19 | Colleen Reitan | Independent Director | Other Acquisition | +671 | -- |
| 2026-05-19 | Colleen Reitan | Independent Director | Other Derivative Acquisition | +1,441 | $298.48 |
| 2026-05-19 | Olivier Brandicourt | Independent Director | Other Acquisition | +671 | -- |
| 2026-05-19 | Olivier Brandicourt | Independent Director | Other Derivative Acquisition | +1,441 | $298.48 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 06:06:04 · For reference only, not investment advice and not tailored to your situation.